Martin Jacko

Company: Aperture Therapeutics

Job title: Chief Executive Officer

Seminars:

Panel Discussion: To What Extent are In Vivo Models Relevant Purely in Evaluating Toxicity & Target Engagement? 11:30 am

Highlighting the need for robust toxicity and bioavailability data showcased in vivo systems Critically evaluating the ability of animal models to predict drug efficacy in treating ALS patients, and the relevance of target engagement data in vivo with different modalities of treatment (including gene therapies) Navigating regulator perspective across FDA, EMA and more to the…Read more

day: Conference Day One Track A

Discovery of Protective Genetic Variants to Develop Disease Modifying Therapeutics for ALS 2:00 pm

Unpacking the role of genetic heterogeneity in ALS Shifting perspective – protective genetic variants in non-neuronal genes that impact disease progression and survival Development of targeted disease modifying therapeuticsRead more

day: Conference Day One Track A PM